KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Novavax (NVAX) over the last 15 years, with Dec 2024 value amounting to $1.8 billion.

  • Novavax's Total Non-Current Liabilities fell 44.11% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 44.11%. This contributed to the annual value of $1.8 billion for FY2024, which is 26.46% down from last year.
  • As of FY2024, Novavax's Total Non-Current Liabilities stood at $1.8 billion, which was down 26.46% from $2.5 billion recorded in FY2023.
  • In the past 5 years, Novavax's Total Non-Current Liabilities registered a high of $2.9 billion during FY2021, and its lowest value of $941.8 million during FY2020.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $2.5 billion (2023), whereas its average is $2.4 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 206.47% in 2021, then declined by 26.46% in 2024.
  • Yearly analysis of 5 years shows Novavax's Total Non-Current Liabilities stood at $941.8 million in 2020, then skyrocketed by 206.47% to $2.9 billion in 2021, then dropped by 1.71% to $2.8 billion in 2022, then dropped by 12.54% to $2.5 billion in 2023, then fell by 26.46% to $1.8 billion in 2024.